217 related articles for article (PubMed ID: 9776302)
1. Isoquinoline derivatives as endogenous neurotoxins in the aetiology of Parkinson's disease.
McNaught KS; Carrupt PA; Altomare C; Cellamare S; Carotti A; Testa B; Jenner P; Marsden CD
Biochem Pharmacol; 1998 Oct; 56(8):921-33. PubMed ID: 9776302
[TBL] [Abstract][Full Text] [Related]
2. Selective dopaminergic neurotoxicity of isoquinoline derivatives related to Parkinson's disease: studies using heterologous expression systems of the dopamine transporter.
Storch A; Ott S; Hwang YI; Ortmann R; Hein A; Frenzel S; Matsubara K; Ohta S; Wolf HU; Schwarz J
Biochem Pharmacol; 2002 Mar; 63(5):909-20. PubMed ID: 11911843
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of [3H]dopamine uptake into striatal synaptosomes by isoquinoline derivatives structurally related to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
McNaught KS; Thull U; Carrupt PA; Altomare C; Cellamare S; Carotti A; Testa B; Jenner P; Marsden CD
Biochem Pharmacol; 1996 Jul; 52(1):29-34. PubMed ID: 8678905
[TBL] [Abstract][Full Text] [Related]
4. Effects of isoquinoline derivatives structurally related to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on mitochondrial respiration.
McNaught KS; Thull U; Carrupt PA; Altomare C; Cellamare S; Carotti A; Testa B; Jenner P; Marsden CD
Biochem Pharmacol; 1996 Jun; 51(11):1503-11. PubMed ID: 8630091
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of complex I by isoquinoline derivatives structurally related to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).
McNaught KS; Thull U; Carrupt PA; Altomare C; Cellamare S; Carotti A; Testa B; Jenner P; Marsden CD
Biochem Pharmacol; 1995 Nov; 50(11):1903-11. PubMed ID: 8615871
[TBL] [Abstract][Full Text] [Related]
6. Isoquinoline neurotoxins in the brain and Parkinson's disease.
Nagatsu T
Neurosci Res; 1997 Oct; 29(2):99-111. PubMed ID: 9359458
[TBL] [Abstract][Full Text] [Related]
7. Nigral cell loss produced by infusion of isoquinoline derivatives structurally related to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
McNaught KS; Thull U; Carrupt PA; Altomare C; Cellamare S; Carotti A; Testa B; Jenner P; Marsden CD
Neurodegeneration; 1996 Sep; 5(3):265-74. PubMed ID: 8910905
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of alpha-ketoglutarate dehydrogenase by isoquinoline derivatives structurally related to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).
McNaught KS; Altomare C; Cellamare S; Carotti A; Thull U; Carrupt PA; Testa B; Jenner P; Marsden CD
Neuroreport; 1995 May; 6(8):1105-8. PubMed ID: 7662887
[TBL] [Abstract][Full Text] [Related]
9. Toxicity to PC12 cells of isoquinoline derivatives structurally related to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
McNaught KS; Thull U; Carrupt PA; Altomare C; Cellamare S; Carotti A; Testa B; Jenner P; Marsden CD
Neurosci Lett; 1996 Mar; 206(1):37-40. PubMed ID: 8848276
[TBL] [Abstract][Full Text] [Related]
10. Endogenous risk factors in Parkinson's disease: dopamine and tetrahydroisoquinolines.
Antkiewicz-Michaluk L
Pol J Pharmacol; 2002; 54(6):567-72. PubMed ID: 12866710
[TBL] [Abstract][Full Text] [Related]
11. N-methyltetrahydropyridines and pyridinium cations as toxins and comparison with naturally-occurring alkaloids.
Herraiz T
Food Chem Toxicol; 2016 Nov; 97():23-39. PubMed ID: 27523294
[TBL] [Abstract][Full Text] [Related]
12. [Metabolic activation of azaheterocyclics induced dopaminergic toxicity: possible candidate neurotoxins underlying idiopathic Parkinson's disease].
Matsubara K
Nihon Hoigaku Zasshi; 1998 Oct; 52(5):301-5. PubMed ID: 10077975
[TBL] [Abstract][Full Text] [Related]
13. N-methylated tetrahydroisoquinolines as dopaminergic neurotoxins.
Naoi M; Dostert P; Yoshida M; Nagatsu T
Adv Neurol; 1993; 60():212-7. PubMed ID: 8420137
[TBL] [Abstract][Full Text] [Related]
14. Intracerebral microdialysis neurotoxicity studies of quinoline and isoquinoline derivatives related to MPTP/MPP+.
Booth RG; Castagnoli N; Rollema H
Neurosci Lett; 1989 May; 100(1-3):306-12. PubMed ID: 2788253
[TBL] [Abstract][Full Text] [Related]
15. Dopamine-derived salsolinol derivatives as endogenous monoamine oxidase inhibitors: occurrence, metabolism and function in human brains.
Naoi M; Maruyama W; Nagy GM
Neurotoxicology; 2004 Jan; 25(1-2):193-204. PubMed ID: 14697894
[TBL] [Abstract][Full Text] [Related]
16. [Contribution of MPTP to studies on the pathogenesis of Parkinson's disease].
Mizuno Y
Rinsho Shinkeigaku; 1989 Dec; 29(12):1494-6. PubMed ID: 2698296
[TBL] [Abstract][Full Text] [Related]
17. Ubiquinone (coenzyme q10) and mitochondria in oxidative stress of parkinson's disease.
Ebadi M; Govitrapong P; Sharma S; Muralikrishnan D; Shavali S; Pellett L; Schafer R; Albano C; Eken J
Biol Signals Recept; 2001; 10(3-4):224-53. PubMed ID: 11351130
[TBL] [Abstract][Full Text] [Related]
18. Dopaminergic neurotoxicity in vivo and inhibition of mitochondrial respiration in vitro by possible endogenous pyridinium-like substances.
Sayre LM; Wang FJ; Arora PK; Riachi NJ; Harik SI; Hoppel CL
J Neurochem; 1991 Dec; 57(6):2106-15. PubMed ID: 1940917
[TBL] [Abstract][Full Text] [Related]
19. Peroxynitrite and mitochondrial dysfunction in the pathogenesis of Parkinson's disease.
Ebadi M; Sharma SK
Antioxid Redox Signal; 2003 Jun; 5(3):319-35. PubMed ID: 12880486
[TBL] [Abstract][Full Text] [Related]
20. Novel toxins and Parkinson's disease: N-methylation and oxidation as metabolic bioactivation of neurotoxin.
Naoi M; Maruyama W; Niwa T; Nagatsu T
J Neural Transm Suppl; 1994; 41():197-205. PubMed ID: 7931227
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
